Featured Research

from universities, journals, and other organizations

Placebo Study Indicates Lower Doses May Effectively Treat ADHD

Date:
May 6, 2003
Source:
University Of North Carolina At Chapel Hill
Summary:
A significant percentage of children with attention-deficit-hyperactivity disorder did just as well when harmless placebos, pills without any specific effect, replaced some of their medications, a study led by two N.C researchers shows.

CHAPEL HILL -- A significant percentage of children with attention-deficit-hyperactivity disorder did just as well when harmless placebos, pills without any specific effect, replaced some of their medications, a study led by two N.C researchers shows.

The findings raise the possibility that some children with these common problems may be effectively treated on lower doses of medication that are supplemented with a placebo. Further research is necessary, the researchers said, to determine the mechanism of the effect that placebos had in treating the disorder.

Dr. Adrian Sandler, a developmental-behavioral pediatrician at the Mission Children's Hospital in Asheville, and Dr. James W. Bodfish, a professor in the University of North Carolina at Chapel Hill department of psychiatry, presented their study findings today (May 3) at the annual meeting of the Pediatric Academic Societies in Seattle.

Sandler and Bodfish have used the results of this initial study to obtain a grant $162,838 per year from the National Institute of Mental Health to study the use of placebos in treating attention-deficit-hyperactivity disorder, or ADHD. That two-year study, involving 150 children with ADHD, is examining the effectiveness of a conditioned placebo treatment, in which decreasing doses of stimulant medications are paired with distinctive placebos.

"This initial study examined the feasibility and potential effectiveness of using placebos along with unusually low doses of stimulant medications to treat children with ADHD. The results of this novel treatment approach were encouraging," said Sandler. "We are proceeding with further research to establish the clinical applications of placebos and to explore mechanisms."

In the study reported today, a group of 26 children ages 7 to 15 received the dose of a stimulant that had kept their ADHD symptoms stable and under good control. Then, the children were given half that dose, both with and without a placebo, in alternating weeks. The children's behavior was monitored with standardized ratings from parents, teachers and clinicians. Parents and the children themselves were all fully informed about the study, so the parents and children knew when they were taking a placebo. Teachers were unaware of the treatment order.

Forty percent of the children in the study responded well to the low dose plus placebo treatment, with equally good ADHD control and fewer side effects, compared with the full dose they had taken previously, based on parent and clinician ratings. Teachers saw little difference among the three conditions.

"Using placebos could have great importance in treating not only ADHD but many other disorders of the central nervous system," Sandler said. "Parents and clinicians alike are concerned about side effects of medications. Our hope is that this treatment approach would allow adequate management of symptoms on unusually low doses of medications. What is especially intriguing is that the placebo treatment was fully disclosed to parents and children. This opens the way to the ethical therapeutic use of placebo effects in order to enhance clinical care."

Many parents are concerned about placing their child on medication, Bodfish said. "Some choose not to treat their child due to concerns about side effects. Conditioning effects and placebo effects are well-established scientific facts. Our preliminary findings suggest that conditioned placebo treatment may allow some children to be effectively treated on lower doses of medication and experience fewer side effects. It's a wonderful example of using basic science to solve a clinical problem."


Story Source:

The above story is based on materials provided by University Of North Carolina At Chapel Hill. Note: Materials may be edited for content and length.


Cite This Page:

University Of North Carolina At Chapel Hill. "Placebo Study Indicates Lower Doses May Effectively Treat ADHD." ScienceDaily. ScienceDaily, 6 May 2003. <www.sciencedaily.com/releases/2003/05/030506073637.htm>.
University Of North Carolina At Chapel Hill. (2003, May 6). Placebo Study Indicates Lower Doses May Effectively Treat ADHD. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2003/05/030506073637.htm
University Of North Carolina At Chapel Hill. "Placebo Study Indicates Lower Doses May Effectively Treat ADHD." ScienceDaily. www.sciencedaily.com/releases/2003/05/030506073637.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins